Caring Brands, Inc. (NASDAQ:CABR) Short Interest Update

Caring Brands, Inc. (NASDAQ:CABR) was the target of a large drop in short interest during the month of July. As of July 31st, there was short interest totaling 427 shares, a drop of 98.8% from the July 15th total of 36,455 shares. Currently, 0.0% of the company’s shares are short sold. Based on an average daily volume of 41,414 shares, the short-interest ratio is presently 0.0 days.

Institutional Trading of Caring Brands

A hedge fund recently bought a new position in Caring Brands stock. Jane Street Group LLC acquired a new stake in Caring Brands, Inc. (NASDAQ:CABR) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 34,446 shares of the company’s stock, valued at approximately $30,000. Jane Street Group LLC owned 0.25% of Caring Brands as of its most recent filing with the Securities & Exchange Commission.

Analyst Ratings Changes

Separately, Weiss Ratings raised Caring Brands from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday, June 11th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company presently has a consensus rating of “Sell”.

Caring Brands Stock Performance

Shares of NASDAQ:CABR traded down $0.07 during midday trading on Wednesday, reaching $1.40. The company’s stock had a trading volume of 14,532 shares, compared to its average volume of 108,807. The firm has a market capitalization of $12.73 million and a price-to-earnings ratio of -2.19. The stock has a 50 day moving average of $1.34. The company has a quick ratio of 5.62, a current ratio of 5.66 and a debt-to-equity ratio of 0.03. Caring Brands has a fifty-two week low of $0.71 and a fifty-two week high of $5.35.

Caring Brands (NASDAQ:CABR) last posted its quarterly earnings results on Tuesday, May 12th. The company reported ($0.27) earnings per share (EPS) for the quarter.

Caring Brands Company Profile

We are a wellness consumer products company. We offer several over-the-counter, or (OTC) and cosmetic, consumer products. Our method of operation is to ensure that (1) the mechanism of action of all products is established, (2) efficacy is determined through controlled clinical trials, (3) products are protected by issued and filed patents, and (4) products have acceptable commercial stability. Prior to its Q3 2022 commercial launch in India as a treatment for vitiligo and psoriasis, Photocil was briefly launched in the United States markets from December 2022 until February 2023, however, was subsequently removed from the market due to insufficient sales resulting from the lack of a dedicated sales and marketing team.